Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8 methoxyl group on survival in liquid media and in human macrophages

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 661-666

  Zhao, Ben Yang ^a   Pine, Richard ^a   Domagala, John ^b   Drlica, Karl ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0033011810     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.661     Document Type: Article

References (29)

1. Agerton, T., S. Valway, B. Gore, C. Pozsik, B. Plikaytis, C. Woodley, and I. Onorato. 1997. Transmission of a highly drug-resistant strain (strain W1) of Mycobacterium tuberculosis. JAMA 278:1073-1077.
2. Bifani, P., B. B. Plikaytis, V. Kapur, K. Stockbauer, X. Pan, M. Lusfty, S. Moghazeh, W. Eisner, T. Daniel, M. Kaplan, J. T. Crawford, J. M. Musser, and B. N. Kreiswirth. 1996. Origin and interstate spread of a New York City multidrug resistant Mycobacterium tuberculosis clone family: adverse implications for tuberculosis control in the 21st century. JAMA 275:452-457.
3. Bloom, B., and C. Murray. 1992. Tuberculosis: commentary on a reemergent killer. Science 251:1055-1064.
4. Cambau, E., and V. Jarlier. 1995. Resistance to quinolones in mycobacteria. Res. Microbiol. 147:52-59.
5. Chen, C.-R., M. Malik, M. Snyder. and K. Drlica. 1996. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J. Mol. Biol. 258:627-637.
6. Dong, Y., C. Xu, X. Zhao, J. Domagala, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984.
7. Drlica, K., C. Xu, J.-Y. Wang, R. M. Burger, and M. Malik. 1996. Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity. Antimicrob. Agents Chemother. 40: 1594-1599.
8. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
9. Frieden, T., P. Fujiwara, R. Washko, and M. Hamburg. 1995. Tuberculosis in New York City - turning the tide. N. Engl. J. Med. 333:229-233.
10. Frieden, T., T. Sterling, A. Pablos-Mendez, J. Kilburn, G. Cauthen, and S. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328:521-526.
11. Garcia, I., A. Pascual, M. C. Guzman, and E. Perea. 1992. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob. Agents Chemother. 36:1053-1056.
12. Horn, D., D. Hewlett, C. Alfalla, A. Patel, K. Brudney, J. Crawford, D. Alland, B. Kreiswirth, S. Opal, and S. Peterson. 1996. Clinical experience with rifampin-isoniazid-streptomycin-ethambutol (RISE)-resistant tuberculosis. Infect. Dis. Clin. Pract. 5:68-72.
13. Ito, T., M. Matsumoto, and T. Nishino. 1995. Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci. Antimicrob. Agents Chemother. 39:1522-1525.
14. Johnson, J. L., J. J. Ellner, and H. Shiratsuchi. 1994. Monocyte-Mycobacterium avium complex interactions: studies of potential virulence factors for humans. Immunol. Ser. 60:263-279.
15. Kitamura, A., K. Hoshino, Y. Kimura, I. Hayakawa, and K. Sato. 1995. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1467-1471.
16. Klopman, G., D. Fercu, J.-Y. Li, H. S. Rosenkranz, and M. R. Jacobs. 1996. Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships. Res. Microbiol. 147:86-96.
17. Kocagoz, T., C. J. Hackbarth, I. Unsal, E. Rosenberg, H. Nikaido, and H. F. Chambers. 1996. Gyrase mutations in laboratory-selected fluoroquinolone-resistant mutants of Mycubacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40:1768-1774.
18. Kreiswirth, B., and A. Moss. 1995. Genotyping multidrug-resistant M. tuberculosis in New York City, p. 199-209. In W. Rom and S. Garay (ed.), Tuberculosis. Little, Brown and Co., Boston, Mass.
19. Pascual, A., I. Garcia, and E. Perea. 1989. Fluorometric measurements of ofloxacin uptake by human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 33:653-656.
20. Power, E., and I. Phillips. 1993. Correlation between umuC induction and Salmonella mutagenicity assay for quinolone antimicrobial agents. FEMS Microbiol. Lett. 112:251-254.
21. Rastogi, N., and M. Blom-Potar. 1990. Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line. Zentbl. Bakteriol. 273:195-199.
22. Sullivan, E. A., B. N. Kreiswirth, L. Palumbo, V. Kapur, J. M. Musser, A. Ebrahimzadeh, and T. R. Frieden. 1995. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345:1148-1150.
23. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of the Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
24. Tsuchiya, S., Y. Kobayashi, Y. Goto, H. Okumura, S. Nakae, T. Konno, and K. Tada. 1982. Induction of maturation in cultured human monocytic leukemia cells by phorbol ester. Cancer Res. 42:1530-1536.
25. van Embden, J. D. A., M. D. Cave, J. T. Crawford, J. W. Dale, K. D. Eisenach, B. Gicquel, P. Hermans, C. Martin, R. McAdam, T. M. Shinnick, and P. M. Small. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J. Clin. Microbiol. 31:406-409.
26. Xu, C., B. N. Kreiswirth, S. Sreevatsan, J. M. Musser, and K. Drlica. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug resistant Mycobacterium tuberculosis. J. Infect. Dis. 174:1127-1130.
27. Voshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272.
28. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.
29. Zhao, X., J.-Y. Wang, C. Xu, Y. Dong, J. Zhou, J. Domagala, and K. Drlica. 1998. Killing of Staphyloccus aureus by C-8-methoxy fluoroquinolones. Antimicrob. Agents Chemother. 42:956-958.